Multidisciplinary considerations in the maintenance treatment of poly(ADP-ribose) polymerase inhibitors for homologous recombination-proficient, advanced-stage epithelial ovarian cancer

CA Cancer J Clin. 2023 Jan;73(1):8-16. doi: 10.3322/caac.21764. Epub 2022 Nov 11.

Authors

Ilana Cass¹, Jill N T Roberts¹, Philip R Benoit², Nicholas V Jensen³

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
² Pharmacy Hematology/Oncology, Norris Cotton Cancer Center, Lebanon, New Hampshire, USA.
³ Medical Genetics, Norris Cotton Cancer Center, Lebanon, New Hampshire, USA.

PMID: 36369877
DOI: 10.3322/caac.21764

No abstract available

MeSH terms

Carcinoma, Ovarian Epithelial / drug therapy
Carcinoma, Ovarian Epithelial / genetics
Female
Homologous Recombination
Humans
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics
Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

Poly(ADP-ribose) Polymerase Inhibitors